Drug Profile


Alternative Names: AERAS-485; MVA-85A; MVA-85A-IMX-313; Tuberculosis subunit vaccine - Emergent BioSolutions/University of Oxford; Tuberculosis vaccine - University of Oxford

Latest Information Update: 04 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Oxford
  • Developer Aeras; University of Oxford
  • Class Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tuberculosis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Tuberculosis

Most Recent Events

  • 21 Aug 2015 The University of Oxford plans a phase I trial for Tuberculosis in the United Kingdom (UKCRN19306)
  • 15 Dec 2014 University of Oxford completes a phase I trial in Tuberculosis (Prevention) in United Kingdom (NCT01879163)
  • 01 Sep 2014 Oxford-Emergent Tuberculosis Consortium and Aeras complete a phase II trial in Tuberculosis (prevention, in adults with HIV infection) in Senegal and South Africa (NCT01151189)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top